Storia in 2 fonti

David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow

Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by the company’s current chief medical officer Zachary Roberts.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo21 h fa

David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow

originale

biopharmadive.com1 g fa

Allogene CEO to step down; Agios drug fails key test

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

Leggi questa versione →

David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow

Allogene CEO to step down; Agios drug fails key test

Timeline cronologica

Allogene CEO to step down; Agios drug fails key test

David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow